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Hans-Georg SchaibleAbstract
Proinflammatory cytokines are major mediators in the pathogenesis of diseases of joints such as rheumatoid arthritis
and osteoarthritis. This review emphasizes that proinflammatory cytokines such as tumor necrosis factor-alpha,
interleukin-1beta, interleukin-6 and interleukin-17 are also mediators of pain by directly acting on the nociceptive
system. Proportions of nociceptive sensory neurons express receptors for these cytokines, and the application of
cytokines rapidly changes the excitability, ion currents and second messenger systems of these neurons. By inducing
persistent sensitization of nociceptive sensory neurons (C- and a proportion of Aδ-fibers) for mechanical stimuli in the
joint (a process called peripheral sensitization), these cytokines significantly contribute to the persistent hyperalgesia
typical for many disease states of the joint. In addition, the disease-associated release of cytokines in the spinal cord
supports the generation of central sensitization. The therapeutic neutralization of proinflammatory cytokines thus not
only reduces the process of inflammation but may directly reduce hyperalgesia and pain by reversing the neuronal
effects of cytokines. It is emerging that different cytokines have different actions on neurons. The neutralization of
tumor necrosis factor-alpha reduces both mechanical and thermal hyperalgesia of the joint. The neutralization of
interleukin-1beta attenuates thermal hyperalgesia whereas the neutralization of interleukin-6 and interleukin-17 mainly
reduces mechanical hyperalgesia. These different effects are partly explained by influencing different target molecules
in sensory neurons. For example, in cultured sensory neurons tumor necrosis factor-alpha and interleukin-1beta
upregulate the TRPV1 ion channel, which is involved in the transduction of heat stimuli, consistent with an effect of
these cytokines in thermal hyperalgesia. By contrast, interleukin-17 upregulates the TRPV4 ion channel, which has a role
in the transduction of mechanical stimuli. Thus, the analgesic potential of neutralizing cytokines seems to depend on
which cytokine is mainly involved in the particular pain state.Introduction
Cytokines are major inflammatory mediators which in-
duce and maintain disease processes such as arthritis. The
recognition that cytokines are major players in rheuma-
toid arthritis (RA) has led to powerful disease-modifying
therapies which are based on the neutralization of proin-
flammatory cytokines such as TNF [1]. Cytokines are also
involved in osteoarthritis (OA) [2] and possibly in other
joint diseases. The success of neutralization of cytokines
in RA and related diseases is documented by the objective
attenuation of the disease process as well as by the sub-
jective experience of the patient. For the patient it is most
impressive when main symptoms such as pain and in-
ability are significantly improved. This review shows that
cytokines play an important role in pain generation. It fo-
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Arthritic pain has typical features. The patient may ex-
perience ongoing pain in the absence of any intentional
stimulation. If mechanical stimuli such as movements in
the working range and palpation of the joint evoke pain
(which is not the case in a healthy joint), the patient is
in a state of pathological mechanical hyperalgesia. If nor-
mally non-painful warm or cold stimuli evoke pain, the
patient experiences thermal hyperalgesia. The basis for
hyperalgesia is the sensitization of the nociceptive (pain)
system for stimuli, in which the threshold for the excita-
tion of nociceptive neurons (and thus for the elicitation
of pain) is lowered and the responses to noxious stimuli
are heightened.
It is usually thought that the neutralization of a proin-
flammatory cytokine attenuates the disease process, and
as a consequence the pain is reduced. Careful observa-
tion of experimental models [3,4] and in patients [5]
showed, however, that neutralization of a cytokine mayThe licensee has exclusive rights to distribute this article, in any medium, for 6
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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nuation of the disease can be documented. These obser-
vations suggest that certain cytokines have a direct role
in the generation and maintenance of pain; that is, by
targeting the nociceptive system itself. For several proin-
flammatory cytokines direct effects on nociceptive neu-
rons have been shown: (a) proportions of nociceptive
(and other) sensory neurons express receptors for cyto-
kines; (b) in cultured isolated sensory neurons the appli-
cation of cytokines may activate second messenger
systems, change the excitability, modifiy ion currents,
and regulate molecules involved in nociception; (c) the
injection of some cytokines into normal tissue evokes
pain behavior in awake animals and enhances the respon-
siveness of nociceptive sensory fibers; (d) the neutralization
of cytokines may reduce pain well in advance of the atte-
nuation of the inflammatory process. Thus, cytokines
contribute to pain indirectly through the generation of in-
flammation which causes the release of many mediators
acting on neurons (for example, prostaglandins) as well as
directly by acting on neurons themselves (Figure 1).
Direct effects of cytokines on nociceptive nerve fibers
have potentially several important consequences. A pain
state may reflect not only the disease process in the joint
but also the direct impact of cytokines on the nervous
system. In this context it is noteworthy that cytokines
are also important mediators of neuropathic pain origin-
ating from injury or disease of neurons themselves [6-8].
Thus, hypothetically, cytokines may also induce patho-
logical changes in the nerve fibers in the long term. In
fact, many chronic pain states associated with joint dis-
eases show changes in the nervous system which suggest
that, in the long term, chronic joint pathology may also
trigger some brain pathology [9].
Nociceptive neurons detect cytokines in the inflamed
joint; however, cytokines may have an impact on neu-
rons also at other sites. First, during arthritis macro-
phages and other inflammatory cells may invade theFigure 1 General diagram of how proinflammatory cytokines
contribute to the generation of pain. The indirect way is induced
by mediators such as prostaglandins that are produced during
inflammation. The direct way indicates direct effects of cytokines on
sensory neurons.dorsal root ganglia (DRG) in which the cell bodies of the
sensory neurons are located [4,10]. Second, cytokines
can be produced and released from glial cells of the
spinal cord which may be activated in the course of joint
diseases [11]. Thus, the pathology of the joint may create
a status in which cytokines within the central nervous
system are also involved in the generation of pain and
possibly of other symptoms. Finally, spinal cytokines
may even influence the peripheral pathology by mo-
difying the efferent neuronal systems which act on
peripheral tissues [12,13]. Figure 2 summarizes sites of
cytokine actions on neurons and neuronal effects of
cytokines.
The following paragraphs concentrate on the proinflam-
matory cytokines TNF-α, IL-6, IL-1β, and IL-17 because
they have been particularly investigated with regard to
joint pain. It is likely that other cytokines will be added as
soon as their roles in joint pain have been investigated.
Tumor necrosis factor-α
TNF-α is a major proinflammatory cytokine in RA [1],
and may also play a role in OA, which often exhibits
marked synovitis [2]. TNF-α also acts on neurons. A
proportion of DRG neurons (the cell bodies of sensory
neurons) in rat express both TNF receptors (TNFR1 and
TNFR2). Some authors identified only TNFR1 in neu-
rons, while localizing TNFR2 in non-neuronal cells in
the DRG (reviewed in [14]). In behavioral experiments
the injection of TNF-α into healthy tissue induced
mechanical and thermal hyperalgesia [15,16].
A single injection of TNF-α into the joint cavity of nor-
mal rat knee joints caused a progressive increase of the re-
sponses of nociceptive C-fibers (which are unmyelinated)
and Aδ-fibers (which are thinly myelinated) to innocuous
and noxious rotation of the joint which was dose-
dependent and persistent. Thus, TNF-α induced a state of
persistent sensitization of joint nociceptors for mechanical
stimuli (a basis for mechanical hyperalgesia), similar to in-
flammation. The effects of TNF-α (and of other cytokines
for comparison) on the responsiveness of nociceptive
C- and Aδ-fibers to mechanical stimulation of the joint
are summarized in Figure 3. The TNF-induced sen-
sitization was prevented by co-administration of the TNF-
neutralizing fusion protein etanercept [14]. Although
some neuronal TNF-α effects may be indirect and involve
other mediators (Figure 1), direct neuronal TNF-α effects
are likely because TNF-α causes hyperexcitability in iso-
lated DRG neurons (see below).
The joint is not the only peripheral site at which TNF-α
may act on neurons. In the acute phase of joint in-
flammation DRGs of the segments with inflammation
show an invasion of ED1-positive macrophages [4,10].
ED1 is equivalent to human CD68 and widely accepted as
a marker for activated macrophages. In DRGs, ED1-
Figure 2 General overview of effects of peripheral and spinal cytokines on joint nociceptors, the spinal cord, and the brain. Note that
each cytokine has its own profile of actions (see text for details). DRG, dorsal root ganglia; TRP, transient receptor potential.
Figure 3 Effects of proinflammatory cytokines on the responsiveness of nociceptive sensory neurons (Aδ- and C-fibers) of the joint to
mechanical stimulation of the joint upon intra-articular injection of different cytokines into the normal knee joint, and long-term
effects of the neutralization of these cytokines on pain behavior in the model of antigen-induced arthritis (AIA).
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Figure 4 Model showing how cytokines sensitize nociceptive
sensory neurons to stimulation. The diagram displays the model
of a sensory ending of a nociceptive sensory neuron in the joint.
The membrane of the neuron expresses ion channels for the
transduction of stimuli (their opening by stimuli causes depolarizing
sensor potentials in the ending) and voltage-gated ion channels for
the regulation of the membrane potential, the excitability and the
generation of the action potentials. In addition, the ending expresses
receptors for cytokines which activate intracellular pathways. The
latter can change the response properties of the ion channels and/
or their expression in the membrane. Membrane receptors for other
mediators (for example, prostaglandins) are not displayed. TRP,
transient receptor potential.
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in close vicinity to neuronal cell bodies and their pro-
cesses, and between neurons and satellite cells [10]. The
invasion was bilateral even if the inflammation (antigen-
induced arthritis (AIA)) was only unilateral. Treatment
with etanercept or infliximab reduced the macrophage
invasion and the expression of vascular cell adhesion
molecule-1-like immunoreactivity (which is involved in
macrophage migration into the tissue), although the AIA
itself was only weakly attenuated by TNF-α neutralization
at this time point [10]. Because the cell bodies of DRG
neurons express cytokine receptors, macrophages may act
on them and cause neuronal effects at this site. Possibly,
the macrophage infiltration into the lumbar DRGs of the
healthy side may be associated with the mechanical hyper-
algesia at the contralateral healthy knee which is observed
in the acute stage of AIA [3,10].
Mechanistically, the sensitization of nociceptive sensory
neurons is produced by enhancing the sensitivity and/or
the expression of ion channels involved in the transduc-
tion of mechanical and thermal stimuli (for example, tran-
sient receptor potential (TRP) ion channels), and/or by
enhancing the sensitivity of voltage-gated ion channels in-
volved in the general excitability of sensory neurons and
the generation of action potentials (Figure 4). The TRPV1
ion channel is opened by heat stimuli, and the elicited ion
influx 'converts' the heat stimulus into an electric sensor
potential. If TRPV1 is sensitized, it opens at lower tem-
peratures than normal, and this drop of threshold is essen-
tial for the generation of thermal hyperalgesia. TRPV4 is a
candidate molecule for the transduction of noxious me-
chanical stimuli, at least under inflammatory conditions
(see below), and it is likely to be involved in the generation
of mechanical hyperalgesia. The sensitization of voltage-
gated Na+ channels can enhance the excitability of neu-
rons; that is, less depolarization is required to evoke an
action potential. Studies on the effects of mediators on
neurons are often performed on isolated and cultured
DRG neurons, which allows direct measurement of neu-
ronal effects.
Bath application of TNF-α increased the excitability and
voltage-gated (tetrodotoxin-resistant) Na+ currents of iso-
lated and cultured DRG neurons within a few minutes,
showing a non-genomic effect of TNF-α on ion channels
involved in the action potential [14,17]. The increase of
Na+ currents depends on TNFR1 and the activation of
p38 MAP kinase, which possibly phosphorylates Na+
channels [17]. The sensitization of joint nociceptors for
mechanical stimulation in vivo by TNF-α (see above) was
also prevented by the p38 inhibitor SB203580, showing
the significance of this pathway for mechanical sen-
sitization [14]. The acute application of TNF-α also sen-
sitized TRPV1 ion channels in cutaneous nociceptive
neurons, resulting in an enhanced heat-evoked release ofthe neuropeptide CGRP (calcitonin gene-related peptide)
from sensory nerve terminals in rat skin [18]. In cultured
DRG neurons long-term incubation with TNF-α for 24 to
48 hours significantly enhanced the proportion of DRG
neurons expressing TRPV1, an effect absent in DRG neu-
rons from tnfr1−/− but not from tnfr2−/− mice [19]. Thus,
TNF-α may further thermal hyperalgesia via upregulation
of TRPV1.
In vivo, cyclooxygenase inhibitors at a dose of 4 mg/kg
completely blocked the TNF-α-induced sensitization of
joint nociceptors for mechanical stimuli whereas lower
doses allowed TNF-α to sensitize joint afferents. Thus,
classical pain therapy at a sufficiently high dose may
antagonize TNF-α effects [14].
As well as the peripheral nociceptive system, the spinal
cord is important for the generation of clinically relevant
pain. During development of inflammation in the joint,
nociceptive spinal cord neurons develop a state of hyper-
excitability (called central sensitization) which increases
the gain of the nociceptive processing [9]. In this context
it is important that TNF-α is produced not only in the
inflamed tissue but also in the spinal cord, namely by
glial cells [11]. Although glial activation is not generally
observed in inflammation [20], astroglia and microglia
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and in models of experimental OA [22]. Both TNF-α in
the joint and TNF-α in the spinal cord affect the nocicep-
tive processing in the spinal cord (Figure 2). TNF-α
injection into the knee joint cavity increased the responses
of spinal cord neurons to mechanical joint stimulation,
while intra-articular injection of etanercept attenuated
inflammation-evoked spinal activity [23]. These effects
can be explained by the modification of the sensory input
into the spinal cord because the sensitization of peripheral
nerve fibers by TNF-α (see above) will increase the affe-
rent barrage during joint stimulation. However, the spinal
application of TNF-α also increased the spinal responses
to joint stimulation. Importantly, spinal application of
either etanercept or an antibody to TNFR1 during the
development of joint inflammation significantly atte-
nuated the generation of inflammation-evoked spinal hy-
perexcitability, which is characterized by widespread pain
sensitization beyond the inflamed joint. These findings in-
dicate that the production and release of TNF-α in the
spinal cord supports the generation of inflammation-
evoked spinal hypersensitivity [23]. Spinal TNF-α was also
implicated in the neuronal control of inflammation in the
joint: intrathecal application of TNF inhibitors signifi-
cantly attenuated joint inflammation [12,13].
From the effects of TNF-α on neurons it should be ex-
pected that neutralization of TNF-α reduces pain. In fact,
this was observed both in animal models (Figure 3) and in
patients with RA. In murine collagen-induced arthritis
(CIA) [24], complete Freund's adjuvant (CFA)-induced
paw inflammation in rat [4], rat AIA [3], and mouse
K/BxN arthritis [21], the neutralization of TNF rapidly re-
duced inflammatory hyperalgesia in the absence of any
other antinociceptive drugs. Typically the antinociceptive
effects of TNF neutralization were already observed on
the first day of treatment even if swelling was only slightly
reduced [3] and gross pathology did not show a difference
between treated and untreated animals [3,4]. Similarly, RA
patients who received infliximab experienced significant
pain reduction after 1 day, although at this early time
point the inflammatory process was not reduced [5].
Intra-articular injection of etanercept reduced responses
of joint nociceptors to rotation of the inflamed joint
within 30 minutes, thus showing that TNF-α neutra-
lization in the joint significantly contributes to the thera-
peutic effect [3].
TNF-α was also implicated in the generation of neuro-
pathic pain. Damaged nerve fibers are activated by TNF-
α released from cells including Schwann cells at the
lesion site. TNFR1 is mainly involved in neuropathic
pain (reviewed in [25]). TNF-α may also contribute to
fibromyalgia because TNF-α application into the normal
masseter muscle evoked a long-lasting reduction of the
mechanical threshold of muscular Aδ-fibers [26].Interleukin-6
IL-6 is a key player in systemic inflammation and arthritis
[27]. IL-6-deficient mice show significantly attenuated AIA
[28]. In a murine model of human TNF-mediated inflam-
mation, IL-6 was particularly involved in inflammation-
evoked osteoclast formation and bone erosion [29]. IL-6
binds either to a membrane-bound IL-6 receptor (IL-6R)
or to a soluble IL-6 receptor (sIL-6R), allowing IL-6 trans-
signaling onto cells that do not express the membrane
receptor. Ultimately the IL-6-IL-6R complex binds to the
transmembrane signal-transducing subunit gp130 [30].
The serum, synovial fluid and tissue of RA patients show
elevated concentrations of both IL-6 and sIL-6R (reviewed
in [31]). While sIL-6R acts as an agonist, circulating
soluble gp130 (sgp130) acts as an antagonist, because it
binds IL-6-sIL-6R complexes and thus prevents trans-
signaling [30]. In murine arthritis models, administration
of sgp130 reduced inflammation [28].
DRG neurons express gp130 [32,33]. Injection of IL-6
into rat hindpaw caused behavioral mechanical hyperal-
gesia [16]. The injection of IL-6 or of IL-6 together with
sIL-6R into a normal knee caused a long-lasting sen-
sitization of nociceptive C-fibers for mechanical stimuli
applied to the joint whereas the responses of Aδ-fibers
remained unaffected on average (Figure 3). The sensi-
tization by IL-6 was prevented by co-administration of
sgp130, but notably sgp130 did not reverse the established
enhanced mechanosensitivity induced by intra-articular
injection of IL6 or IL-6-sIL-6R [34]. Thus, IL-6-induced
persistent hyperexcitability is difficult to reverse. Similarly,
injection of IL-6 into skeletal muscle enhanced the re-
sponses to prostaglandin E2 injected into the muscle for
at least 24 hours, showing long-term 'priming' of nocicep-
tive neurons [35].
Knock-out mice lacking gp130 specifically in sensory
DRG neurons (SNS-gp130−/−) showed reduced inflam-
matory and tumor-induced pain [36]. Thus, gp130 in af-
ferent neurons is a key regulator of the induction and
maintenance of mechanical hypersensitivity [37].
Neurons and glial cells of the spinal cord also express
gp130. The membrane receptor IL-6R is mainly found in
glial and endothelial cells and sparsely in neurons of the
central nervous system (reviewed in [38]). Originally,
spinal IL-6 was mainly investigated in the context of
neuropathic pain [6,7]; however, rats suffering from ar-
ticular CFA inflammation and from generalized AIA also
showed increased spinal levels of IL-6 (reviewed in [38]).
The application of IL-6-sIL-6R either into the knee
joint or topically to the spinal cord increased the re-
sponses of spinal neurons to mechanical stimulation of
the knee and other parts of the leg, including an expan-
sion of the receptive field size of the neurons, showing
the potential of IL-6 to induce central sensitization.
Development of knee inflammation evoked significant
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attenuated the generation of spinal hyperexcitability du-
ring development of inflammation. However, spinally ap-
plied sgp130 did not reverse established hyperexcitability
if inflammation had developed fully [38].
The induction of persistent neuronal hyperexcitability
that is difficult to reverse raises the intriguing question
of whether neutralization of IL-6 alleviates arthritic pain.
In the AIA model a single injection of sgp130 into the
knee joint at the time of arthritis induction caused a sig-
nificant long-term reduction of mechanical hyperalgesia,
although acute arthritis per se was barely attenuated
[31]. By contrast, repeated intraperitoneal injection of
sgp130 in the course of AIA reduced mechanical hyper-
algesia only weakly, at a time point where AIA is already
in the process of remission (Figure 3) [31]. This beha-
vioral pattern of IL-6 neutralization corresponds to the
neuronal effects of IL-6, indicating that endogenous IL-6
indeed plays a significant role in the generation of
arthritic joint pain but that the IL-6-induced hyperexcit-
ability is difficult to reverse once it is established. These
findings suggest, therefore, that IL-6 may play an im-
portant role in the chronification and poor reversibility
of pain.
A caveat is that sgp130 also regulates the IL-6-related
cytokines leukemia inhibiting factor and oncostatin M,
but sgp130 has a lower affinity for leukemia inhibiting fac-
tor and oncostatin M than for the IL-6-sIL-6R complex,
and it prevents mainly trans-signaling by IL-6-sIL-6R
complexes [30].
Interleukin-1β
IL-1β is abundantly expressed in RA [1] and OA [2].
Mice deficient for the naturally occurring inhibitor of
IL-1 develop spontaneously erosive arthritis. Neutra-
lization of IL-1β reduced CIA but not adjuvant arthritis
and AIA. Bone loss was reduced in CIA and adjuvant
arthritis (reviewed in [39]). Anakinra, an IL-1 receptor
(IL-1R1) antagonist, had only limited efficacy in human
RA [1].
IL-1β binds to the cell surface receptors IL-1RI and
IL-1RII. IL-1RI transduces the biological signal of IL-1β
into cells and IL-1RII serves as a decoy receptor. Sensory
neurons express only IL-1RI [40,41]. In rats 26.4 ± 2.9%
of all DRG neurons of small and medium size expressed
IL-1R1 but, interestingly, during immunization in the
AIA model the proportion increased up to 60% of DRG
neurons and persisted during subsequent AIA [39].
IL-1β contributes to pain and hyperalgesia (reviewed in
[42]). In rat, intraplantar injection of IL-1β induced cuta-
neous hyperalgesia and transient ongoing discharges [43].
Recordings from joint afferents showed that IL-1β sensi-
tizes nociceptive C-fibers of the joint to mechanical sti-
muli. Interestingly, however, the sensitivity of nociceptiveAδ-fibers was simultaneously significantly reduced by
IL-1β (Figure 3). The reason for the latter effect is un-
known. Because Aδ- and C-fibers converge onto the same
spinal cord neurons, the increase of the C-fiber input into
the spinal cord is at least partly compensated for by the
decrease of the Aδ-fiber input after IL-1β [39].
In isolated DRG neurons, IL-1β increased excitability
via p38 MAP kinase and enhanced tetrodotoxin-resistant
Na+ currents [44], suppressed voltage-gated K+ channels
[45], and increased TRPV1 currents [41]. The exposure of
DRG neurons to 1 nmol/l (but not to 10 nmol/l) IL-1β
significantly upregulated the proportion of DRG neurons
expressing the TRPV1 channel (prevented by the IL-1 re-
ceptor antagonist IL-1Ra) [39]. In addition, IL-1β changes
the activity of the enzyme G-protein-coupled receptor
kinase 2 (GRK2). GRK2 regulates the responsiveness of
multiple G-protein-coupled receptors, and downregula-
tion of GRK2 by IL-1β reduces the internalization of these
receptors and thus promotes nociception [46].
Because the pattern of effects of IL-1β on sensory neu-
rons of the joint (opposite effects on C- and Aδ-fibers)
is different to that of TNF-α and IL-6, it is an intriguing
question how neutralization of IL-1β affects pain in arth-
ritis. In the AIA model, treatment with anakinra had
only marginal effects on the severity of arthritis and
mechanical hyperalgesia, which may result from the
opposite effects of IL-1β on C- and Aδ-fibers [39]
(Figure 3). But anakinra consistently and significantly re-
duced the thermal hyperalgesia, along with a reduction
of the expression of TRPV1 in DRGs during AIA [39].
Because the major burden of RA is mechanical hyperalge-
sia and not thermal hyperalgesia, anakinra may not cause
pain relief in RA. By contrast, in gout, a 'hot' inflamma-
tion, thermal hyperalgesia may be more important, and in
gout neutralization of IL-1β is analgesic [47].
Interleukin-17
Recently, IL-17 became the focus of research because it
was identified as a major mediator of immunity and in-
flammation, such as in RA, multiple sclerosis and other
disorders [1,48]. IL-17A, the prototype member, induces
the production of mediators of innate and adaptive im-
munity [48,49]. The synovial fluid of RA patients exhibits
elevated IL-17A levels [48]. Reduction of IL-17A amelio-
rated disease activities in preclinical models of RA whereas
overexpression of IL-17A aggravated CIA [48]. The use of
monoclonal antibodies against IL-17 in humans effectively
reduced inflammatory diseases [49,50].
The receptor IL-17RA is ubiquitously expressed. In
DRG sections and cultured DRG neurons the majority
of neurons show cytoplasmatic expression of IL-17RA.
An antibody directed to the amino-terminal extracellular
domain of IL-17RA labeled 43 ± 4% of cultured DRG
neurons, which were mainly small and medium sized
Figure 5 Profile of different cytokines in the generation of
hyperalgesia. IL-17, IL-6, and TNF-α cause mechanical hyperalgesia,
whereas thermal hyperalgesia is mainly induced by TNF-α and IL-1β.
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fects a proportion of sensory neurons.
Behaviorally, the intra-articular injection of IL-17 caused
experimental hyperalgesia [52]. Wild-type and Il17a−/−
mice showed similar nociceptive mechanical and thermal
thresholds in the absence of inflammation but after induc-
tion of zymosan-induced paw inflammation (zymosan
activates lymphoid tissue inducer-like cells as an innate
source of IL-17 and IL-22) the mechanical threshold was
less reduced in Il17a−/− than in wild-type mice, indicating
that IL-17A contributes to mechanical hyperalgesia even
when paw swelling was identical in Il17a−/− and wild-type
mice. Wild-type and Il17a−/− mice did not differ in the
development of thermal hyperalgesia [51], except at a later
stage at which IL-17A may also activate inflammatory cas-
cades which change thermal sensitivity [52,53].
A single injection of IL-17A into the normal knee joint
caused a dose-dependent and slowly developing and per-
sistent increase of the responses of nociceptive C-fibers to
both innocuous and noxious rotation of the joint [54]
(doses were similar to those used in behavioral experi-
ments in mice [52,53]). The IL-17A-induced sensitization
was prevented by neither etanercept nor sgp130; thus, IL-
17A itself sensitizes joint afferents [54]. Interestingly, noci-
ceptive Aδ-fibers were only sensitized at a deteriorating
dose for C-fibers, suggesting that IL-17A mainly sensitizes
C-fibers (Figure 3). At a very low dose, IL-17A reduced
the responses of Aδ-fibers and may therefore reduce the
input from the periphery [54].
Cellular studies support neuronal effects of IL-17. In
isolated and cultured rat DRG neurons, IL-17A evoked
phosphorylation of protein kinase B (PKB/Akt) and
extracellular-regulated kinase (ERK) within 5 minutes.
IL-17A generated hyperexcitability of small to medium-
sized DRG neurons within 5 minutes after bath applica-
tion, showing regulation of voltage-gated ion channels
[54]. After long-term exposure to IL-17A more DRG
neurons exhibited pERK [51], a mechanism possibly in-
volved in long-term hyperexcitability.
Incubation of DRG neurons with IL-17A did not up-
regulate TRPV1 (consistent with a lack of IL-17 on heat
sensitivity); however, IL-17A upregulated TRPV4. The
TRPV4 ion channel is gated by temperature in the
innocuous range with a maximum at 37°C, but is also con-
sidered a candidate molecule for the transduction of
noxious mechanical stimuli, at least under inflammatory
conditions [55]. Although TRPV4 is not the only TRP
channel involved in mechanical hyperalgesia, the upregu-
lation of TRPV4 by IL-17A in conjunction with the induc-
tion of mechanical hyperexcitability by IL-17A reinforces
a functional role of TRPV4 in the state of mechanical
hyperalgesia.
In the AIA mouse model an antibody against IL-17
slightly reduced the swelling, but significantly reducedthe guarding score and secondary mechanical hyperal-
gesia at the paws [54], thus further supporting a role of
IL-17A in mechanonociception (Figure 3). In human
RA, a fully human antibody (AIN457) to IL-17A reduced
inflammation and significantly decreased the number of
joints with pressure pain as early as 1 week and up to 16
weeks after a single or two injections of the antibody
[50], showing a role for IL-17 in human mechanical
hyperalgesia.
Since IL-17RA is also expressed in satellite cells of
DRGs, IL-17A may also be involved in neuropathic pain
because satellite cells play a role in the pathological de-
structive and repair processes in DRGs in the aftermath
of neuronal damage [56].
Conclusion
The data show that cytokines are not only mediators of
disease processes but are also pain mediators by directly
acting on the nociceptive system. Through comparison
of the effects of different cytokines on sensory neurons
the concept begins to emerge that different cytokines are
involved in particular qualities of pain, such as mecha-
nical or thermal hyperalgesia (Figure 5). The specific
effects of particular cytokines result from their different
effects on Aδ- and C-fibers and from their different
target molecules of nociception (for example, TRPV1 ver-
sus TRPV4). This conclusion is substantially supported by
the treatment studies using the AIA model, which show
that neutralization of different cytokines reduced the par-
ticular quality of hyperalgesia that is generated by a par-
ticular cytokine. Furthermore, it is becoming evident from
both the effects of cytokines on nerve fibers and the treat-
ment studies that the neuronal effects of some cytokines
(for example, TNF-α) can be more easily reversed than
the effects of others (for example, IL-6), suggesting that
different cytokines have a different potential to induce
chronic pain states. Available clinical data also support
this concept (for example, the rapid reduction of mechan-
ical hyperalgesia by neutralization of TNF-α in animal
models of arthritis and in RA patients).
As an extension of this concept it may be speculated
that the pain pattern in a patient and the likelihood to
Schaible Arthritis Research & Therapy 2014, 16:470 Page 8 of 9
http://arthritis-research.com/content/16/5/470reduce the pain by cytokine neutralization depends on
the cytokines which are predominant in the pathogenesis
of the disease. If TNF-α is mainly involved, the chance
may be high to achieve pain reduction with neutra-
lization of TNF-α because TNF-α effects are reversible.
By contrast, if IL-6 is predominant, the chance of pain
reduction may be much smaller because IL-6-induced
sensitization is more difficult to reverse. If the inflam-
mation is hot (for example, during acute gout), the
neutralization of IL-1β may cause pain reduction be-
cause TRPV1 is involved whereas this treatment will not
reduce the mechanical hyperalgesia in chronic RA.
Careful monitoring of the effects of neutralization of
cytokines on pain in the clinical setting may help to sup-
port or reject this concept.
Further challenges for research are to expand our
knowledge about the role of the cytokine-induced neur-
onal activation in the (reflex) control of inflammation
[12,13]. Furthermore, it has to be explored whether the
reduction of brain activity by cytokine neutralization [5]
is based on the neutralization of peripheral cytokine ef-
fects or whether cytokines in the brain may also be in-
volved in pain generation. For example, TNF-α has a
significant impact on synaptic functions in brain regions
such as the hippocampus [57], and it is possible, there-
fore, that changes in TNF-α are partly responsible for
symptoms associated with chronic inflammation.Note: This article is part of the series ‘At the interface between
immunology and neurology in rheumatic diseases’, edited by
Rainer Straub. Other articles in this series can be found at
http://arthritis-research.com/series/neurology.Abbreviations
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